Product Name: Rizatriptan benzoate CAS NO: 145202-66-0
Phosphonium,[3-(dimethylamino)propyl]triphenyl-, bromide (1:1);
Chemical & Physical Properties:
Appearance : white to off-white crystalline powder
Boiling Point: 504.8℃ at 760mmHg
Rizatriptan benzoate and its orally disintegrating tablets are mainly suitable for the treatment of migraine. Rizatriptan benzoate was originally developed by Merck in the United States. It was first listed in the United States in June 1998. The dosage forms listed abroad include ordinary tablets and orally disintegrating tablets. Since the market of triptan drugs, they have gradually become the first-line drugs for the treatment of migraine due to their remarkable efficacy and low side effects.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.